GlassScriptPhysician profile
Jayaprakash N Shetty
NPI 1720081896
$12,997.63
in general payments reported to CMS, 2019-2025
30 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,561 · 2020: $2,689 · 2021: $2,858 · 2022: $1,853 · 2023: $1,575 · 2024: $200 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,036.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,253.96 | 2019-2024 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,621.80 | 2019-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $1,563.59 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $1,350.19 | 2019-2023 | |
| Novo Nordisk INC | $1,185.43 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $985.90 | 2019-2023 | |
| Pfizer INC. | $526.84 | 2019-2025 | |
| Amgen INC. | $475.30 | 2019-2023 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $342.02 | 2019-2020 | |
| Lilly USA, LLC | $334.28 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Ironwood Pharmaceuticals, INC | $296.76 | 2019 | |
| Merck Sharp & Dohme LLC | $264.63 | 2019-2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $245.99 | 2021-2023 | |
| Astellas Pharma US INC | $213.02 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $140.83 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $133.11 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $125.76 | 2025 | Lumryz |
| Puma Biotechnology, INC. | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $121.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $117.09 | 2019-2022 | |
| Allergan, INC. | $111.59 | 2019 | |
| Exact Sciences Corporation | $103.67 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $74.27 | 2021 | |
| Abbvie INC. | $70.66 | 2021-2023 | Qulipta, Linzess, Viberzi |
| Eyevance Pharmaceuticals LLC | $58.58 | 2021 | |
| Watermark Medical, INC. | $39.91 | 2023 | Ares Home Sleep Testing Device |
| Eisai INC. | $35.71 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $30.12 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.86 | 2019 | |
| Sumitomo Pharma America, INC. | $23.56 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayaprakash Shetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.